Article
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
The New England journal of medicine - 14 Jul 2022
Jänne Pasi A, Riely Gregory J, Gadgeel Shirish M, Heist Rebecca S, Ou Sai-Hong I, Pacheco Jose M, Johnson Melissa L, Sabari Joshua K, Leventakos Konstantinos, Yau Edwin, Bazhenova Lyudmila, Negrao Marcelo V, Pennell Nathan A, Zhang Jun, Anderes Kenna, Der-Torossian Hirak, Kheoh Thian, Velastegui Karen, Yan Xiaohong, Christensen James G, Chao Richard C, Spira Alexander I
Abstract excerpt
BACKGROUND: Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: In a registrational phase 2 cohort, we evaluated adagrasib (600 mg orally twice daily) in patients with KRASG12C -mutated non-small-cell lung...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.